Shaolin Capital Management’s Revelation Biosciences, Inc. Unit REVBU Stock Holding History

Shaolin Capital Management’s Portfolio REVBU Stock Details REVBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-234,158	Closed	-$2.53M	–	538
2020 Q4	$2.53M	Buy	+234,158	New	+$2.38M	0.18%	147

Other funds holding REVBU

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

CFN

Cordasco Financial Network Naples, Florida $138M AUM 10.5% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Shaolin Capital Management's REVBU Position: Q1 2021 in Review

Shaolin Capital Management sold out of Revelation Biosciences, Inc. Unit (REVBU) in Q1 2021, closing a stake of 234,158 shares — an estimated $2.53M sold.

Shaolin Capital Management first reported a position in REVBU in Q4 2020 and held it in 1 quarter. The position peaked at $2.53M in Q4 2020. 4 funds tracked by Wall St. Rank hold REVBU as of Q1 2021.

Shaolin Capital Management reported no remaining Revelation Biosciences, Inc. Unit position as of Q1 2021 after selling out during the quarter.
Shaolin Capital Management sold 234,158 Revelation Biosciences, Inc. Unit shares in Q1 2021, an estimated $2.53M.
Shaolin Capital Management first reported a position in Revelation Biosciences, Inc. Unit in Q4 2020 and held it in 1 quarter.
Shaolin Capital Management's Revelation Biosciences, Inc. Unit position peaked at $2.53M in Q4 2020.
4 funds tracked by Wall St. Rank held Revelation Biosciences, Inc. Unit as of Q1 2021.

Based on Shaolin Capital Management's 13F filing for Q1 2021, filed 17 May 2021.